Neuberger Berman Group LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Neuberger Berman Group LLC

  • $123 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023
BUY
$23.9 - $35.38 $1.1 Million - $1.62 Million
45,839 Added 130.7%
80,912 $2.57 Million
Q1 2023

May 12, 2023
SELL
$22.82 - $35.32 $831,081 - $1.29 Million
-36,419 Reduced 50.94%
35,073 $855,000
Q4 2022

Feb 13, 2023
BUY
$25.35 - $31.96 $1.81 Million - $2.28 Million
71,492 New
71,492 $2.25 Million

Others Institutions Holding CERE

# of Institutions
9
Shares Held
5.01M
Call Options Held
3.3K
Put Options Held
0
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Neuberger Berman Group LLC Portfolio

Follow Neuberger Berman Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Neuberger Berman Group LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email